This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround ...

Key Takeaways Vertex Pharmaceuticals shares surged Tuesday after announcing promising results from a clinical trial.Analysts ...

Acurx Pharmaceuticals Inc ACXP shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session. The move may reflect continued investor reaction to ...

Now, it’s worth noting Stock Advisor’s total average return is 941 % — a market-crushing outperformance compared to 194% for ...

Investing.com -- Vertex Pharmaceuticals (NASDAQ:VRTX) shares rose 6% to $488.52 in premarket trading Thursday after the company reported successful results from a late-stage trial of its kidney ...

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 4.98% on an annualized basis producing an average annual return of 13.51%. Currently, Vertex Pharmaceuticals ...

The company's pipeline features almost 40 programs in late-stage clinical testing. These clinical trials are testing new drug candidates and seeking additional approvals for drugs such as Tremfya.

Over the next 5 years, Gland Pharma plans to invest approximately Rs 20 bn in capex, primarily towards BFS and ophthalmic lines as well as capex towards CDMO contracts. Brownfield expansions will ...